Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca PLC

http://www.astrazeneca.com

Latest From AstraZeneca PLC

Novo Files Suit Over IRA As It Joins Others In Signing On To Price Negotiations

The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.

Medicare Pricing Debate

Japan Approves Leqembi, All Eyes Now On Extended Pricing Discussions

Japan's latest batch of product approvals includes high-profile Alzheimer's drug Leqembi (lecanemab), along with Alhemo (concizumab) for hemophilia, Phozevel (tenapanor) for hyperphosphatemia and others. Eyes are now on the shape of use guidelines and monitoring requirements for Leqembi, along with how its extended NHI  reimbursement pricing process will develop. All going well, it could reach the market by the end of the year.

Japan Approvals

Japan Approves Leqembi, All Eyes Now On Extended Pricing Discussions

Japan's latest batch of product approvals includes high-profile Alzheimer's drug Leqembi (lecanemab), along with Alhemo (concizumab) for hemophilia, Phozevel (tenapanor) for hyperphosphatemia and others. Eyes are now on the shape of use guidelines and monitoring requirements for Leqembi, along with how its extended NHI  reimbursement pricing process will develop. All going well, it could reach the market by the end of the year.

Japan Approvals

Stock Watch: The Rise Of Biotech Platforms

In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.

Stock Watch Platform Technologies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Alexion Pharmaceuticals Inc.
    • Almirall Sofotec
    • AlphaCore Pharma
    • Amplimmune, Inc.
    • Ardea Biosciences, Inc.
    • Arrow Therapeutics
    • Aviron
    • Cellective Therapeutics, Inc.
    • Definiens
    • IntraBiotics Pharmaceuticals, Inc.
    • KuDOS Pharmaceuticals Ltd.
    • Medimmune
    • Novexel
    • Neogene Therapeutics, Inc.
    • Omthera Pharmaceuticals
    • Pearl Therapeutics
    • Spirogen Ltd.
    • TeneoTwo, Inc.
    • U.S. Bioscience
    • Acerta Pharma
    • ZS Pharma
UsernamePublicRestriction

Register